Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer

The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer

“…Although FT is a reasonable option for the treatment of localised PCa, its widespread acceptance as a standard approach has encountered specific challenges. This is attributed, among other factors, to technological advancements that enabled progress in the field of FT, leading to heterogeneity in patient selection, treatment approaches, and follow‐up methods [5]. This trajectory began with the introduction of MRI and fusion biopsies and will continue with the development of prostate‐specific membrane antigen positron emission tomography imaging and artificial intelligence in the future.…”